FDA Determines Regulatory Review Period for Patent Extension of NEUTERSOL

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of NEUTERSOL, a veterinary drug product, following the submission of patent extension applications to the US Department of Commerce.